Development and Testing of AIDS Vaccines

Recent advances in delineating the molecular biology of human immunodeficiency virus type 1 (HIV-1) have led to innovative approaches to development of a vaccine for acquired immunodeficiency syndrome (AIDS). However, the lack of understanding of mechanisms of protective immunity against HIV-1, the...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 1988-07, Vol.241 (4864), p.426-432
Main Authors: Koff, Wayne C., Hoth, Daniel F.
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - prevention & control
Adjuvants, Immunologic
AIDS
AIDS vaccines
AIDS/HIV
Animal models
Animals
Antibodies
Antigenic Variation
Clinical Trials as Topic
Disease Models, Animal
Epitopes
Ethics
Genetic aspects
HIV
HIV (Viruses)
HIV - genetics
HIV - immunology
HIV 1
human immunodeficiency virus 1
Humans
Immunity
Infections
Jurisprudence
Medical ethics
Medical research
T lymphocytes
Vaccination
Vaccination & vaccines
Vaccines
Vaccines, Synthetic
Viral Proteins - immunology
Viral Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in delineating the molecular biology of human immunodeficiency virus type 1 (HIV-1) have led to innovative approaches to development of a vaccine for acquired immunodeficiency syndrome (AIDS). However, the lack of understanding of mechanisms of protective immunity against HIV-1, the magnitude of genetic variation of the virus, and the lack of effective animal models for HIV-1 infection and AIDS have impeded progress. The testing of AIDS vaccines also presents challenges. These include liability concerns over vaccine-related injuries; identification of suitable populations for phase 3 efficacy studies; balancing the ethical obligation to counsel research subjects to avoid high-risk behavior with the necessity to obtain vaccine efficacy data; and the effect of vaccine-induced seroconversion on the recruiting and welfare of trial volunteers. Several candidate AIDS vaccines are nevertheless currently under development, and some are undergoing phase 1 clinical trials. Rapid progress will depend on continued scientific advancement in conjunction with maximum use of resources, open information and reagent exchange, and a spirit of international collaboration.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.3293212